Dipeptidyl Peptidase 3 (DPP3), is a dynamic biomarker for assessing DPP3 release – one major cause of cardiac depression. The enzyme is at the core of a recently discovered disease mechanism leading…
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as…
Microtiter plate assays
IVD tests for SphingoTec’s proprietary biomarkers are made available as sphingotest® microtiter plate tests. Get in touch to order our products or request more information.
…
Welcome to our blog!
Here’s where we will share current and exciting information about acute care diagnostics, innovative biomarkers, recent research and development stories. We will also have guest…
SphingoTec has identified shock and loss of kidney function as major pathways leading to mortality in critical care and we have developed biomarkers diagnosing, predicting, and monitoring these major…
The Acute Disease Quality Initiative (ADQI) has published a consensus statement that strongly recommends using innovative biomarkers to improve the management of sepsis-associated acute kidney injury…
Diagnostic company SphingoTec is pleased to announce the appointment of Dr. Florian Uhle as the company's new Medical Director. Dr. Uhle is a subject matter expert in translating innovations into…
